Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP deep phenotyping study of brigatinib in ALK-positive non-small cell lung cancer
2024-513947-94-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: PFS 1st-line treatment. Started Oct 2024; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2024-513947-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513947-94-00.